Mahadevia Ankit 4
4 · Spero Therapeutics, Inc. · Filed Feb 3, 2022
Insider Transaction Report
Form 4
Mahadevia Ankit
Director
Transactions
- Award
Stock Option (Right to Buy)
2022-02-01+187,730→ 187,730 totalExercise: $11.18Exp: 2032-02-01→ Common Stock (187,730 underlying) - Award
Common Stock
2022-02-01+134,168→ 278,204 total
Footnotes (3)
- [F1]Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting Person's continued service through the applicable vesting date.
- [F2]Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Amount also includes 212,387 RSUs held by the Reporting Person.
- [F3]The shares underlying this option vest as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.